CROI 2013: Challenges and Opportunities for the Development of Long-acting Antiretrovirals [VIDEO]
- Details
- Category: HIV Treatment
- Published on Friday, 15 March 2013 00:00
- Written by Gregory Fowler
Marta Boffito from Chelsea and Westminster Hospital in London presented an overview of some of the challenges and opportunities in the development of long-acting antiretroviral agents for HIV treatment and prevention in a themed discussion at the 20th Conference on Retroviruses and Opportunistic Infections (CROI 2013) last week in Atlanta.
Presidio and Boehringer Ingelheim Will Collaborate on Interferon-free Hepatitis C Combo
- Details
- Category: Experimental HCV Drugs
- Published on Friday, 15 March 2013 00:00
- Written by Presidio
Presidio Pharmaceuticals and Boehringer Ingelheim will jointly conduct a Phase 2a trial to evaluate an all-oral combination containing its NS4A inhibitor PPI-668 plus faldaprevir and BI 207127, with or without ribavirin, for people with hard-to-treat genotype 1a hepatitis C virus.
CROI 2013: Simeprevir and Faldaprevir Boost Interferon Response Rates for HIV/HCV Coinfected
- Details
- Category: Experimental HCV Drugs
- Published on Monday, 11 March 2013 00:00
- Written by Liz Highleyman
Adding the hepatitis C virus (HCV) protease inhibitors simeprevir or faldaprevir to pegylated interferon plus ribavirin produces higher response rates and the potential for shorter treatment for HIV/HCV coinfected people, according to 2 studies presented last week at the 20th Conference on Retroviruses and Opportunistic Infections (CROI 2013) in Atlanta.
CROI 2013: Adding Telaprevir Increases Acute Hepatitis C Cure Rate for HIV+ Men
- Details
- Category: HIV/Hepatitis Coinfection
- Published on Tuesday, 12 March 2013 00:00
- Written by Liz Highleyman
Adding telaprevir (Incivek) to pegylated interferon and ribavirin shortens the duration of therapy and improves the likelihood of a cure for HIV positive men with acute sexually transmitted hepatitis C virus (HCV), according to study findings presented at the 20th Conference on Retroviruses and Opportunistic Infections (CROI 2013) last week in Atlanta.
CROI 2013: Cancer Incidence After Starting Antiretroviral Therapy [VIDEO]
- Details
- Category: HIV-Related Conditions
- Published on Monday, 11 March 2013 00:00
- Written by Gregory Fowler
Rates of AIDS-related cancers start to fall not long after initiation of antiretroviral therapy (ART), but non-AIDS cancers rise with increasing time on therapy, according to study findings presented last week at the 20th Conference on Retroviruses and Opportunistic Infections (CROI 2013) in Atlanta.
More Articles...
- CROI 2013: Simeprevir + Sofosbuvir Demonstrates Good Early Cure Rate With or Without Ribavirin
- CROI 2013: Zinc Finger Gene Therapy Leads to Durable T-Cell Recovery, Sangamo Says
- CROI 2013: Early Antiretroviral Therapy May Reduce HIV Reservoir Size [VIDEO]
- CROI 2013: Does Hormonal Contraception Raise the Risk of HIV Infection? [VIDEO]
Web Design and Development by